<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583544</url>
  </required_header>
  <id_info>
    <org_study_id>TC-2216-232-CLP-001</org_study_id>
    <nct_id>NCT00583544</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers</brief_title>
  <acronym>SRD</acronym>
  <official_title>A Double Blind, Sequential, Ascending Single Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Study of TC-2216 in Healthy Young Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targacept Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targacept Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous&#xD;
      system (CNS) neurobiological disorders in anticipation of seeking an indication in depression&#xD;
      and/or anxiety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hematology, biochemistry, urine analysis, vital sign, ECG, adverse events.</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma and urine pharmacokinetics, Pharmaco EEG, Bond-Lader Visual Analogue Scal</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-2216</intervention_name>
    <description>Multiple ascending dose groups will be explored.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects aged 18-40 years old (both ages included).&#xD;
&#xD;
          2. Subjects must be in good health as determined by their medical history, physical&#xD;
             examination, psychological examination, ECG, vital signs, standard EEG and laboratory&#xD;
             tests. A volunteer with a clinical abnormality may be included only if the&#xD;
             Investigator or his designee considers that the abnormality will not introduce&#xD;
             additional risk factor for the subject's health, or interfere with the study&#xD;
             objectives.&#xD;
&#xD;
          3. Subjects with a body mass index within the range 18-29 kg/m2 and a weight within the&#xD;
             range of 60-90 kg.&#xD;
&#xD;
          4. Non-smoker subjects (a cotinine test will be performed at screening and Day -1&#xD;
&#xD;
          5. Subjects must be able to refrain from consuming xanthine containing beverages, and&#xD;
             must refrain from intensive physical exercise during the study conduct (until the end&#xD;
             of study visit).&#xD;
&#xD;
          6. Subjects must have signed an informed consent form indicating that they understand the&#xD;
             purpose of and procedures required for the study and are willing to participate in the&#xD;
             study and comply with the study procedures and restrictions.&#xD;
&#xD;
          7. Subjects must be affiliated with, or a beneficiary of, a French social security&#xD;
             system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Potential subjects who meet any of the following criteria will be excluded from&#xD;
        participating in the study:&#xD;
&#xD;
          1. Any clinically relevant acute or chronic diseases which could interfere with the&#xD;
             subjects safety during the trial, or expose them to undue risk, or which could&#xD;
             interfere with the study objectives.&#xD;
&#xD;
          2. History or presence of gastrointestinal, hepatic, or renal disease or other condition&#xD;
             known to interfere with the absorption, distribution, metabolism or excretion of&#xD;
             drugs.&#xD;
&#xD;
          3. Any history of drug or other significant allergy.&#xD;
&#xD;
          4. Likely to need any treatment (including dental care) during the study period.&#xD;
&#xD;
          5. Donation of one or more units of blood within 90 days prior to the screening.&#xD;
&#xD;
          6. Use of any prescription or over-the-counter medication within 14 days prior to&#xD;
             admission on Day-1 (not including paracetamol in the range of 1gr/day). In addition&#xD;
             any medications with central effects are prohibited for a period equal to 5 x&#xD;
             half-life prior to admission (Day-1), should this period be longer than 14 days.&#xD;
&#xD;
          7. Alcohol consumption &gt; 40 g alcohol/day (1 glass (25 cl) of beer with 3째 of alcohol =&#xD;
             7.5 g, or 1 glass (25 cl) of beer with 6째 of alcohol = 15 g, or 1 glass (12.5 cl) of&#xD;
             wine with 10째 of alcohol = 12 g, or 1 glass (4cl) of aperitif with 42째 of alcohol = 17&#xD;
             g).&#xD;
&#xD;
          8. Positive alcotest at screening and Day -1 .&#xD;
&#xD;
          9. Positive test result on hepatitis B surface antigen, hepatitis C antibody.&#xD;
&#xD;
         10. Positive test result on HIV 1 and 2 serology.&#xD;
&#xD;
         11. Excessive daily consumption of xanthines containing drinks (i.e &gt; 500 mg/day of&#xD;
             caffeine).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Targacept Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>Targacept Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forenap Pharma</name>
      <address>
        <city>Rouffache</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.targacept.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <last_update_submitted>July 17, 2008</last_update_submitted>
  <last_update_submitted_qc>July 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Geoffrey Dunbar, Vice President, CDRA</name_title>
    <organization>Targacept, Inc</organization>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Healthy Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

